Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease.
Bridging the Brain Disease Knowledge Gap Through Computational Modeling and Systems Biology
Potential T cell epitopes of Mycobacterium tuberculosis that can instigate molecular mimicry against host: implications in autoimmune pathogenesis.
Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.
Mu opioid receptor activation modulates Toll like receptor 4 in murine macrophages.
Endogenous opioids regulate the expression of inducible nitric oxide synthase by splenocytes.
Mutations affecting segment number and polarity in Drosophila.
Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Association mapping of disease loci, by use of a pooled DNA genomic screen.
MRI in multiple sclerosis: a review of the current literature.
Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial.
MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis.
Oral dalfampridine improves standing balance detected at static posturography in multiple sclerosis.
No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
Unraveling the secrets of white matter - Bridging the gap between cellular, animal and human imaging studies.
ATX-MS-1467 - Positive Immunological data in Multiple Sclerosis: Final Phase I/IIa data shows safety and tolerability, plus efficacy
Multiple sclerosis: Spinal cord grey matter loss correlates with disability in MS.
Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.
From "Wheelchair Circuit" to "Wheelchair Assessment Instrument for People with Multiple Sclerosis": Reliability and Validity Analysis of a Test to Assess Driving Skills in Manual Wheelchair Users With Multiple Sclerosis.
Don't stress about it!: Is stress management a disease-modifying therapy for multiple sclerosis?
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis
Imaging In The Cell

Pages